BioMedNewsBreaks

MondayOct 31, 2022 1:52 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,”…

Continue Reading

MondayOct 31, 2022 1:12 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Pleased with Safety Profile of Its PRV-002 Concussion Treatment

Odyssey Health (OTC: ODYY) recently announced the completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial. “Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to determine drug safety. A total of 40 healthy subjects took part in the study. In Cohort I, eight patients received a low dose of the drug, and in Cohort II, patients received a high dose of the drug. The second Cohort reflected the success of the first, where the drug was well tolerated and proved safe with no severe adverse events reported,”…

Continue Reading

ThursdayOct 27, 2022 11:37 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its EMBARK Psychedelic-Assisted Psychotherapy Training Program have announced the graduation of highly skilled facilitators who are now prepared to handle a range of experiences that participants of psychedelic-assisted psychotherapy may undergo. The training program includes foundational training enabling participants to learn the skills necessary to provide ethical care for and work with psychedelic-assisted psychotherapy patients. EMBARK is a leading-edge model of psychedelic-assisted psychotherapy that is implemented in Cybin’s phase 1/2a trial, which is designed to evaluate CYB003, Cybin’s investigational deuterated psilocybin analog. CYB003 has potential to…

Continue Reading

WednesdayOct 26, 2022 1:35 pm

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Expedite Return to Work, Play Following Concussive Episode

Odyssey Health (OTC: ODYY), a medical company with a focus in the area of life-saving medical solutions, has developed a fully synthetic, non-naturally occurring neurosteroid known as PRV-002 intended to treat concussion or mild traumatic brain injury (“mTBI”). “Designed to be administered within a few minutes of a concussive episode, PRV-002 induces an intracellular steroid receptor in brain cells, with the stimulation of this receptor activating multiple gene response elements that promote transcription of anti-inflammatories, antioxidants and efflux channels that remove excess fluid and debris. To put it simply, PRV-002 is intended to reduce swelling, oxidative stress and inflammation, and…

Continue Reading

WednesdayOct 26, 2022 12:43 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Approval of Second Clinical Trial Site for Phase 1 Study

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has added Rutgers Cancer Institute of New Jersey (“RCINJ”) as a clinical trial site for its phase 1 CycloSam study. RCINJ has been approved to begin enrolling patients into the study, which will evaluate the effectiveness of CycloSam in treating patients with bone cancer. According to the announcement, RCINJ is part of Rutgers Health and is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, a designation granted to institutions based on scientific leadership, resources and track record of…

Continue Reading

WednesdayOct 26, 2022 12:31 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its VP of R&D, James Kuo, M.D. M.B.A, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. According to the update, Silo Pharma is a sponsor of the three-day event slated to take place Nov. 3-5, 2022, in Miami, Florida. Dr. Kuo will speak on the Mainstream Pharma and Psychedelics panel scheduled for Saturday, Nov. 5, on the Science Main Stage. “It will be an honor to join other industry leaders as…

Continue Reading

WednesdayOct 26, 2022 11:19 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it is supporting initiatives to raise awareness of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Epidermolysis Bullosa Global Awareness Week is Oct. 25-31, 2022. “In severe cases of epidermolysis bullosa, or EB, the very fragile skin tears easily and forms painful blisters and open wounds that do not heal quickly,” said Alexandra Mancini, SVP of Clinical and Regulatory Affairs for InMed. “EB is a very important but rare disease that does not get the attention it deserves. EB Awareness…

Continue Reading

TuesdayOct 25, 2022 12:06 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q3 2022 Results Conference Call

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced that it will hold a conference call at 4:30 p.m ET on Thursday, Nov. 10, 2022. HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the call, during which time they will discuss the company’s results for the third quarter ended Sept. 30, 2022, and review recent announcements, ongoing initiatives, and key 2022 and anticipated 2023 milestones, followed by a question-and-answer period. A presentation will accompany the…

Continue Reading

MondayOct 24, 2022 2:31 pm

BioMedNewsBreaks – Octane’s Upcoming Forum to Showcase Visionary Speakers, Latest Advances in Medical Technology Sector

Octane, an organization leading the Southern California technology and medical technology business ecosystem, today announced that the 2022 Medical Innovation Forum will be held on Oct. 27-28 at the Irvine Marriott in Irvine, California. The two-day event will feature the most visionary speakers from the medical technology sector, showcase the latest advances, and offer access to unparalleled educational opportunities and the potential to network, explore synergies and foster long-term partnerships with fellow professionals. Investors looking for untapped opportunities will benefit from one-on-one, private meetings organized with fully vetted, early stage companies that are at the cutting edge of innovation in the medical…

Continue Reading

MondayOct 24, 2022 1:49 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at LD Micro Main Event XV

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, has announced that its Director of Investor Relations, Joshua Phillipson, will attend and present at the LD Micro Main Event XV. The leading small cap investor conference is taking place in Los Angeles on Oct. 25 to 27, 2022, and will showcase more than 200 companies. Phillipson is scheduled to present at 9 a.m. PT on Tuesday, Oct. 25, in Track 3, and will discuss BiondVax’s investment case, including its highly experienced leadership team, innovative…

Continue Reading